Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986322

Next Previous
Drug Profile

BMS 986322

Alternative Names: BMS-986322

Latest Information Update: 23 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antipsoriatics
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis

Most Recent Events

  • 06 Aug 2024 Bristol-Myers Squibb completes a phase II trial in Psoriasis in the US, Canada, Poland, Australia, Japan, and the United Kingdom (Unspecified route) (NCT05730725)
  • 22 Dec 2023 Bristol-Myers Squibb completes a phase I pharmacokinetics trial (In volunteers) in USA (unspecified route) (NCT06088264)
  • 13 Dec 2023 Bristol-Myers Squibb completes a phase I drug-drug interaction trial in healthy volunteers in USA (PO) (NCT05615012)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top